President Donald Trump announced Thursday his nomination of Chris Klomp to serve as deputy secretary of the Department of Health and Human Services. The decision was made in coordination with HHS Secretary Robert F. Kennedy Jr. and Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz. Klomp currently holds multiple leadership positions within the administration, including chief counselor at HHS and deputy administrator at CMS.
Trump described the nominee as a rising star within his administration, emphasizing his rapid advancement through key healthcare positions. The president highlighted Klomp’s background as an entrepreneur and his ability to earn trust across various roles. According to Trump’s announcement on Truth Social, Klomp demonstrates strong leadership principles and maintains a deep commitment to serving American citizens while addressing systemic healthcare challenges.
Multiple leadership roles within healthcare administration
Klomp’s professional profile reveals extensive responsibilities across the healthcare bureaucracy. He simultaneously serves as chief counselor of HHS, deputy administrator of the Centers for Medicare & Medicaid Services, director of the Center for Medicare within CMS, and senior advisor to the HHS secretary. This portfolio of positions demonstrates his involvement in both policy development and operational management across federal healthcare programs.
The president characterized HHS as a massive and complex organization, expressing confidence in Klomp’s operational capabilities. Trump stated that the nominee understands precisely how to manage the department’s extensive operations. The announcement emphasized Klomp’s current performance leading Medicare programs and overseeing daily administrative functions.
Drug pricing policy implementation highlighted
Trump’s announcement specifically referenced Klomp’s role in implementing the administration’s Most Favored Nation drug pricing policy. The president framed this initiative as addressing what he described as foreign countries benefiting from American pharmaceutical development without paying proportional costs. The policy aims to align U.S. drug prices with those paid by other nations for identical medications.
- Experience in building large-scale business operations prior to government service
- Current oversight of Medicare program administration and daily CMS operations
- Leadership in implementing major pharmaceutical pricing reforms
- Coordination with multiple senior healthcare officials including Kennedy and Oz
The president claimed substantial reductions in drug prices over the past year, attributing these changes to policy reforms. Trump described Klomp’s business background as providing the toughness necessary to drive significant healthcare system changes. The announcement positioned the nominee as capable of executing reforms requiring both technical expertise and political determination.
Collaboration with Kennedy and Oz emphasized
The nomination announcement stressed the collaborative decision-making process involving three key figures. Trump indicated that he, Secretary Kennedy, and Administrator Oz jointly agreed on Klomp’s promotion to deputy secretary. This approach suggests coordination among the administration’s healthcare leadership team in structuring department management.
Kennedy currently leads HHS following his confirmation earlier in Trump’s term, while Oz oversees CMS, the agency responsible for Medicare and Medicaid programs serving over 140 million Americans. Klomp’s elevation to deputy secretary would position him as the second-ranking official within the department, responsible for operational coordination across multiple agencies and programs.
America First healthcare reform agenda outlined
Trump concluded his announcement by connecting Klomp’s nomination to broader policy objectives. The president stated that the nominee prioritizes American interests and will work to reform healthcare systems. The announcement referenced the administration’s “Make America Great and Healthy Again” initiative, linking personnel decisions to policy goals.
The deputy secretary position requires Senate confirmation, though Trump’s announcement did not specify timing for the confirmation process. If confirmed, Klomp would assume formal authority over department operations while maintaining his current portfolio of responsibilities. The position involves coordinating policy implementation across HHS agencies including the Centers for Disease Control and Prevention, Food and Drug Administration, and National Institutes of Health.
Trump’s characterization of Klomp as a potential star suggests expectations for continued advancement within the administration. The nomination reflects the administration’s approach of promoting individuals with business backgrounds into senior government positions. The announcement emphasized results-oriented leadership and commitment to policy objectives as key qualifications for the deputy secretary role.
